ArticleSTAR protocols2022
Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4.
Mohamad Zandian, Suk Min Jang, Catherine Lachance, Arpan Acharya, Siddappa N Byrareddy, Jacques Côté, Tatiana G Kutateladze
Open access · goldAbstract read
In one paragraphArticle in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 5 institutions in 2 countries.
Mohamad ZandianDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Suk Min JangLaval University Cancer Research Center, CHU de Québec-UL Research Center-Oncology Division, Quebec City, QC G1R 3S3, Canada.
Catherine LachanceLaval University Cancer Research Center, CHU de Québec-UL Research Center-Oncology Division, Quebec City, QC G1R 3S3, Canada.
Arpan AcharyaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68131, USA.
Siddappa N ByrareddyDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68131, USA. Electronic address: sid.byrareddy@unmc.edu.
Jacques CôtéLaval University Cancer Research Center, CHU de Québec-UL Research Center-Oncology Division, Quebec City, QC G1R 3S3, Canada. Electronic address: jacques.cote@crchudequebec.ulaval.ca.
Tatiana G KutateladzeDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: tatiana.kutateladze@cuanschutz.edu.
Université Laval · CANebraska Medical Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USUniversity of Nebraska Medical Center · US
Funding
Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection-supplementR01DA052845 · NIDA · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BYRAREDDY, SIDDAPPA N, MOHAN, MAHESH · 2020 to 2024
$4.0MLimiting HIV establishment and maintenace by preserving intestinal immunityR01AI129745 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N, PAIARDINI, MIRKO · 2017 to 2020
$3.3MTargeting acetylated histone H4 by MLL4R01AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2021 to 2025
$2.1MMolecular analysis of ASH1LR01CA252707 · NCI · UNIVERSITY OF COLORADO DENVER · PI TATIANA G KUTATELADZE · 2020 to 2026
$1.9MThe role of JADE in HBO complexesR01HL151334 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.8MEpigenetic mechanisms for regulation of p300R01GM135671 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2023
$1.4MInterdomain crosstalk in MORC3R01GM125195 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2017 to 2021
$1.3MTargeting acetylated histone H4 by MLL4R56AG067664 · NIA · UNIVERSITY OF COLORADO DENVER · PI KUTATELADZE, TATIANA G · 2020 to 2020
$512kNCI NIH HHS R01 CA252707NHLBI NIH HHS R01 HL151334NIAID NIH HHS R01 AI129745NIA NIH HHS R01 AG067664NIA NIH HHS R56 AG067664NIDA NIH HHS R01 DA052845NIGMS NIH HHS R01 GM125195NIGMS NIH HHS R01 GM135671
6 · The paper itselfAbstract
The SARS-CoV-2 envelope (E) protein hijacks human BRD4 (bromodomain and extra-terminal domain protein 4). Here, we describe a protocol to characterize the interaction of the acetylated E protein with BRD4 in vivo. We detail steps to use NMR spectroscopy to map the binding interface and include steps to monitor the effect of BRD4 inhibitors in SARS-CoV-2-infected human lung bronchial epithelial cells. This approach could be applied to study interactions involving other viral and human proteins. For complete details on the use and execution of this protocol, please refer to Vann et al. (2022).
Indexed as
COVID-19Nuclear ProteinsBromodomain Containing ProteinsCell Cycle ProteinsHumansSARS-CoV-2Transcription FactorsViral ProteinsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsNuclear ProteinsTranscription FactorsViral ProteinsCell BiologyMicrobiologyMolecular BiologyNMRProtein BiochemistryStructural Biology
Identifiers
PMID36595918
PMCPMC9613806
OpenAlexW4307460328
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390